BR112017012491A2 - composição - Google Patents

composição

Info

Publication number
BR112017012491A2
BR112017012491A2 BR112017012491A BR112017012491A BR112017012491A2 BR 112017012491 A2 BR112017012491 A2 BR 112017012491A2 BR 112017012491 A BR112017012491 A BR 112017012491A BR 112017012491 A BR112017012491 A BR 112017012491A BR 112017012491 A2 BR112017012491 A2 BR 112017012491A2
Authority
BR
Brazil
Prior art keywords
salt
aqueous composition
composition
compound
prostaglandin
Prior art date
Application number
BR112017012491A
Other languages
English (en)
Inventor
Sawai Isamu
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of BR112017012491A2 publication Critical patent/BR112017012491A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L23/00—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
    • C08L23/02—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers not modified by chemical after-treatment
    • C08L23/10—Homopolymers or copolymers of propene
    • C08L23/12—Polypropene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

uma técnica é fornecida para reduzir a descoloração de uma composição aquosa contendo um derivado de isoquinolina halogenada durante a preservação em temperatura alta. uma composição aquosa compreendendo um composto representado pela fórmula (1): em que x representa um átomo de halogênio, ou um sal deste, ou um solvato do composto ou o sal deste, e uma prostaglandina.
BR112017012491A 2014-12-12 2015-12-11 composição BR112017012491A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014252182 2014-12-12
PCT/JP2015/084803 WO2016093345A1 (ja) 2014-12-12 2015-12-11 組成物

Publications (1)

Publication Number Publication Date
BR112017012491A2 true BR112017012491A2 (pt) 2018-01-09

Family

ID=56107522

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017012491A BR112017012491A2 (pt) 2014-12-12 2015-12-11 composição

Country Status (11)

Country Link
US (2) US20170368075A1 (pt)
EP (1) EP3231430A4 (pt)
JP (2) JP5951921B1 (pt)
KR (1) KR20170093836A (pt)
CN (1) CN107106569B (pt)
BR (1) BR112017012491A2 (pt)
CA (1) CA2970254A1 (pt)
MX (1) MX2017007574A (pt)
MY (1) MY178880A (pt)
SG (1) SG11201704735WA (pt)
WO (1) WO2016093345A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6236167B2 (ja) * 2014-09-25 2017-11-22 興和株式会社 医薬品
BR112021015799A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Métodos para aumentar o crescimento em pacientes pediátricos com doença colestática do fígado
JP2020200296A (ja) * 2019-06-13 2020-12-17 久貴 藤本 角膜内皮障害の予防及び／又は治療のための薬剤
US11786538B2 (en) 2019-12-11 2023-10-17 Somerset Therapeutics, Llc Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties
WO2021182596A1 (ja) * 2020-03-13 2021-09-16 興和株式会社 上眼瞼溝深化改善剤
CN111518028A (zh) * 2020-05-12 2020-08-11 中国药科大学 一种一氧化氮供体型ripasudil衍生物及其制备方法和用途
JP2022120120A (ja) * 2022-06-13 2022-08-17 東亜薬品株式会社 眼科用水性組成物及びプロスタグランジンＦ２α誘導体の含量の低下を抑制する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU743607B2 (en) * 1998-07-14 2002-01-31 Alcon Laboratories, Inc. Prostaglandin product
CN100425241C (zh) * 2002-08-29 2008-10-15 参天制药株式会社 由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂
JP4482726B2 (ja) * 2002-08-29 2010-06-16 参天製薬株式会社 Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
US7718797B2 (en) * 2004-03-16 2010-05-18 Asahi Kasei Pharma Corporation Fasudil-containing preparation and method of improving stability thereof
US20060142270A1 (en) * 2004-12-23 2006-06-29 Kowa Co., Ltd. Preventing or treating agent for glaucoma
JP4800720B2 (ja) * 2005-09-21 2011-10-26 興和株式会社 点眼用組成物
TW202126308A (zh) * 2011-02-04 2021-07-16 日商興和股份有限公司 青光眼治療劑與高眼壓症治療劑
JP2013035802A (ja) * 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
TWI699205B (zh) * 2014-12-12 2020-07-21 日商興和股份有限公司 用於預防或治療青光眼之藥物療法

Also Published As

Publication number Publication date
JP2016155871A (ja) 2016-09-01
WO2016093345A1 (ja) 2016-06-16
JPWO2016093345A1 (ja) 2017-04-27
MX2017007574A (es) 2018-03-01
EP3231430A4 (en) 2018-08-08
US20180289719A1 (en) 2018-10-11
SG11201704735WA (en) 2017-07-28
US20170368075A1 (en) 2017-12-28
JP5951921B1 (ja) 2016-07-13
MY178880A (en) 2020-10-21
CA2970254A1 (en) 2016-06-16
CN107106569A (zh) 2017-08-29
KR20170093836A (ko) 2017-08-16
EP3231430A1 (en) 2017-10-18
CN107106569B (zh) 2020-07-28

Similar Documents

Publication Publication Date Title
BR112017012491A2 (pt) composição
BR112017006148A2 (pt) produto farmacêutico
BR112017012483A2 (pt) composição aquosa
BR112017012487A2 (pt) composição aquosa
BR112017006253A2 (pt) novos compostos
BR112017002827A2 (pt) derivado de quinolina altamente puro e método para produção do mesmo
BR112017006149A2 (pt) preparação farmacêutica
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
BR112018011475A2 (pt) compostos e métodos para modulação de quinase e indicação para a mesma
BR112015018188A2 (pt) composição e método para o controle de pestes
AR097158A1 (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
BR112017003898A2 (pt) análogos de dioxolano de uridina para o tratamento de câncer
BR112020016020A8 (pt) Inibidor de atr e aplicação do mesmo
BR112017011316A2 (pt) derivados heterocíclicos e uso destes
BR112017000242A2 (pt) composto, cristal, inibidor de axl, medicamento, composição farmacêutica, métodos para tratamento de uma doença, para prevenção de metástases de câncer, para superar a resistência a drogas de um câncer e para inibir a aquisição de resistência a drogas de um câncer, e, uso de um composto
BR112017011921A2 (pt) agente para tratamento de deformação de cabelo
BR112014026266A2 (pt) derivado de quinazolidinadiona
BR112016025356A2 (pt) 4-fenilpiperidinas substituido, sua preparação e utilização
BR112017012146A2 (pt) derivado de di-hidroindolizinona
BR112015024075A2 (pt) compostos de piridinilpirazoloquinolina
BR112016024238A2 (pt) uso de composições aquosas de redução de desvio
EA201692270A1 (ru) Производные нафтиридиндиона
AR099767A1 (es) Derivados del ácido acético azaindol y su uso como moduladores del receptor de prostaglandina d2
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
BR112017006150A2 (pt) composição aquosa

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2700 DE 04-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.